BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33886156)

  • 1. Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial.
    Ogasawara M; Miyashita M; Yamagishi Y; Ota S
    Ther Apher Dial; 2021 Aug; 25(4):415-424. PubMed ID: 33886156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
    Ota S; Miyashita M; Yamagishi Y; Ogasawara M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5563-5572. PubMed ID: 34919493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
    Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
    Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial.
    Nagai K; Adachi T; Harada H; Eguchi S; Sugiyama H; Miyazaki Y
    Anticancer Res; 2020 Oct; 40(10):5765-5776. PubMed ID: 32988904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.
    Ogasawara M; Miyashita M; Yamagishi Y; Ota S
    Ther Apher Dial; 2019 Jun; 23(3):279-288. PubMed ID: 31033141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer.
    Ogasawara M; Miyashita M; Yamagishi Y; Ota S
    Ther Apher Dial; 2020 Oct; 24(5):482-491. PubMed ID: 32524770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
    Ito Z; Kan S; Bito T; Horiuchi S; Akasu T; Yoshida S; Kajihara M; Hokari A; Saruta M; Yoshida N; Kobayashi M; Ohkusa T; Shimodaira S; Okamoto M; Sugiyama H; Koido S
    Oncology; 2019; 97(3):135-148. PubMed ID: 31216557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
    Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M
    Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
    Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
    Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.
    Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
    Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.
    Tsukinaga S; Kajihara M; Takakura K; Ito Z; Kanai T; Saito K; Takami S; Kobayashi H; Matsumoto Y; Odahara S; Uchiyama K; Arakawa H; Okamoto M; Sugiyama H; Sumiyama K; Ohkusa T; Koido S
    World J Gastroenterol; 2015 Oct; 21(39):11168-78. PubMed ID: 26494971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
    Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
    Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.
    Takakura K; Koido S; Kan S; Yoshida K; Mori M; Hirano Y; Ito Z; Kobayashi H; Takami S; Matsumoto Y; Kajihara M; Misawa T; Okamoto M; Sugiyama H; Homma S; Ohkusa T; Tajiri H
    Anticancer Res; 2015 Jan; 35(1):555-62. PubMed ID: 25550602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
    Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
    Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.
    Nishida S; Ishikawa T; Egawa S; Koido S; Yanagimoto H; Ishii J; Kanno Y; Kokura S; Yasuda H; Oba MS; Sato M; Morimoto S; Fujiki F; Eguchi H; Nagano H; Kumanogoh A; Unno M; Kon M; Shimada H; Ito K; Homma S; Oka Y; Morita S; Sugiyama H
    Cancer Immunol Res; 2018 Mar; 6(3):320-331. PubMed ID: 29358173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
    Yanagisawa R; Koizumi T; Koya T; Sano K; Koido S; Nagai K; Kobayashi M; Okamoto M; Sugiyama H; Shimodaira S
    Anticancer Res; 2018 Apr; 38(4):2217-2225. PubMed ID: 29599342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses.
    Ogasawara M; Miyashita M; Ota S
    Ther Apher Dial; 2018 Jun; 22(3):266-277. PubMed ID: 29851270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
    Bassani-Sternberg M; Digklia A; Huber F; Wagner D; Sempoux C; Stevenson BJ; Thierry AC; Michaux J; Pak H; Racle J; Boudousquie C; Balint K; Coukos G; Gfeller D; Martin Lluesma S; Harari A; Demartines N; Kandalaft LE
    Front Immunol; 2019; 10():1832. PubMed ID: 31440238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.